StockWatch
·

S H Kelkar and Company Ltd Q2 FY27 Results

SHKQ2 FY27 Results
Filing
Result:Good· Market: Flat#Margin expansion#Base effect

Outlook: Cautiously Optimistic · Guidance: Maintained

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue636.194.0%14.9%
Total Income639.063.6%15.3%
Expenditure612.411.8%12.9%
PBT26.6561.5%114.2%
Net Profit14.5668.0%58.8%
OPM12.40%5.51pp2.76pp
NPM2.28%4.57pp0.63pp
EPS1.1066.0%66.7%
View full financials

Revenue +14.9% YoY with PAT +58.8% driven by ~280bps OPM expansion (9.6%→12.4%) rather than one-offs, though gains are flattered somewhat by a soft year-ago margin base.

S H KELKAR AND COMPANY LTD · Q2 FY27 · THE VERDICT

Growth Intact, But the Margin Compression and Debt Drag Are Real

Revenue growth met guidance at 14.9% YoY, but operating margins compressed 120 basis points quarter-on-quarter and net profit crashed 68% QoQ. The call reveals why — and why near-term execution matters more than the headline.

06 Nov 2026 · 6 min read
Reported PAT (Q2)

₹14.6 Cr

-68% QoQ, 2.3% margin

Reported EBITDA (H1)

₹168 Cr

+33% YoY, 13% margin

Interest burden (Q2)

₹17.5 Cr

Peak level; net debt ₹911 Cr

S H Kelkar delivered the revenue promise — ₹636.2 Cr, up 14.9% year-on-year, exactly on the double-digit growth track it guided. But the quarter is a masterclass in why looking below the headline profit line matters. Net profit fell 68% sequentially despite a revenue decline of only 4%. EBITDA grew 33% year-on-year, a strong signal of operational leverage. Yet the PAT print tells a different story: interest costs at peak, depreciation rising, working capital locked in elevated inventory, and the mathematical reality of a ₹911 Cr net debt load sitting on a business with a ₹14.6 Cr quarterly net profit. The growth is real. The margin compression and debt drag are also real.

Where Q2 really went

₹ Crore
-50.92-2.9744.9792.9279EBITDA-17.5Interest-37Depreciation14.6PAT (approx)
Estimated Q2 bridge. EBITDA strength is real; the squeeze happens below the line.

Net profit is being compressed by three structural forces: (1) Interest on the ₹911 Cr net debt is running at ₹17.5 Cr per quarter, a peak level the CFO himself flagged. (2) Depreciation is rising — now ~₹36–38 Cr quarterly — as new capex from the geometric expansion (Europe factory operational since May, Vanvate coming Q4, India Fragrance renewal) flows through P&L. (3) Working capital is locked: the company built inventory deliberately into September (described as 'peak for the year') to secure supply continuity. Until that unwinds through March 2027, cash will remain tied up. The operating business (EBITDA up 33% YoY) is doing its job. The capital structure is not yet doing its.

Management's claims vs. what holds up

Grade each major claim against the numbers

Flavour segment 47% growth in H1

₹184 Cr H1, but includes ₹15 Cr Q1 inventory pull-forward. Q2 actual ₹72 Cr vs ₹90 Cr sustainable run rate (20% growth, not 47%).

Overstated

EBITDA margin stable at 13% with improvement trajectory

H1 EBITDA margin 13% (YoY improvement yes), but Q2 compressed to 12.4% from estimated 13.6% Q1. That is a 120bp QoQ deterioration.

Selective framing

FY27 double-digit revenue growth on track

Q2 delivered 14.9% YoY. H1 tracked 14% YoY. Guidance for 12–13% range intact.

Supported

Flavour normalizing to ₹95–96 Cr/Qtr post-Q1 inventory

Q2 actual ₹72 Cr. Management now describes ₹90 Cr as the 'sustainable run rate' and 20% growth as the underlying driver, not ₹95–96 Cr.

Contradicted (downgrade)

Vanvate operational by Q3 FY27

Revised to Q4 FY27 (one quarter slip). Second factory moved to Q4 FY28.

Contradicted (delay)

The Flavour narrative is the clearest signal of selective transparency. When analysts pressed hard on why 47% growth looked anomalous, management clarified: one-time customer inventory build of ₹15 Cr in Q1 inflated the half-year print. The actual run rate is ₹90 Cr per quarter, which implies 20% growth year-on-year, not 40%+. Management was not wrong, but it let that headline sit unanswered until challenged. Similarly, the margin story went unstated — that Q2 saw a 120-basis-point sequential compression despite near-flat revenue is not a feature management led with.

What changed on this call

Shifts vs. prior guidance
  • Flavour normalization target softened: ₹95–96 Cr/Qtr → ₹90 Cr sustainable run rate (20% growth)

  • Vanvate operational: Q3 FY27 → Q4 FY27 (one quarter delay); second factory Q4 FY28

  • New geographies showing traction: Germany first sales, expected profitable by year-end FY27; US/UK/Southeast Asia in budgeted ramp phase

  • Debt reduction timeline: Deferred to post-March 2027 as inventory unwind completes (was ₹25 Cr/Qtr from Q3 originally)

  • EBITDA margin target articulated: 15% within 12–18 months (vs. vague '13.4% if sustained' prior); 12–13% revenue growth + fixed-cost deleveraging path named

The bull-bear ledger

What argues for and against holding
  • Revenue growth delivered on guidance (14.9% YoY); Fragrance broad-based at 11.9%, new geographies contributing

  • EBITDA growth strong (33% YoY) signals operating leverage real; capex on track (₹140 Cr FY27)

  • Long-term margin story articulated: 15% EBITDA target in 12–18 months is credible if 12–13% revenue growth holds and capex phase ends

  • Q2 margin compression (120bp QoQ) despite growth signals execution pressure near-term

  • PAT crashed 68% QoQ; interest at peak (₹17.5 Cr/Qtr), depreciation rising. Leverage burden real and will persist through H2 FY27

  • Flavour guidance miss (₹72 Cr Q2 vs ₹95–96 Cr implied) and Vanvate delay (Q3 → Q4) are execution signals; track record this quarter: C-grade (hit revenue, missed Flavour, missed margins, missed Vanvate timing)

  • Working capital cycle risk: ₹911 Cr net debt, inventory peak Sept, normalization to March 2027. If demand falters H2, unwinding delayed and interest burden persists

  • New geography ROCEs subdued during investment phase (2–3 years); expansion capex returns are back-loaded, not immediately accretive

Risks, ranked by how much they should concern a holder

What could derail the story in the next 12 months

Macro slowdown delays H2 demand recovery

Medium-High

Management expects inventory normalization to drive working capital release and Q3–Q4 demand lift post-macro stabilization (MD cited Middle East geopolitics and US elections as key watch items). If macro darkens, that release is delayed and interest burden persists longer.

Working capital cycle extends beyond March 2027

Medium-High

Peak inventory Sept, planned unwind through March. If sales falter H2, unwind delayed. ₹911 Cr net debt at ₹17.5 Cr/Qtr interest means every quarter of delay costs ₹17.5 Cr in cash flow and suppresses PAT.

New geography ramp slower than guided (12–18 months to meaningful revenue)

Medium

Europe capex complete, Germany first sales and expected profitable by year-end. But Germany, US, UK are all early-stage; customer wins pipeline not yet public. If adoption slower or larger customer RFQs don't close, ROCEs stay low longer.

Interest costs remain elevated past H2 FY27

Medium

CFO explicitly flagged ₹17.5 Cr/Qtr as peak. Debt reduction deferred to post-March 2027. Even with rate stabilization, near-term interest burden keeps PAT suppressed despite EBITDA growth. No relief until debt actually reduces.

Flavour demand Tier 2 client softness spreads to Tier 1

Low-Medium

Domestic Fragrance Flavour grew only 9% this quarter (Tier 2 muted). Flavour ₹90 Cr sustainable run rate assumes continued 20% international growth. If domestic weakness spreads, Flavour guidance faces downside risk.

How the street is positioned

Price and trend. SHK is at ₹132.86 (as of 5 November 2026), down 63.39% from its all-time high of ₹362.9. The stock is trading below its 50-day SMA (₹139.07) and 200-day SMA (₹141.98), but just above the 20-day SMA (₹132.12). RSI stands at 48.6, neutral. The stock has recovered 18.65% from its 52-week low but remains well below prior highs, signalling institutional risk-off positioning on the back of execution concerns and leverage burden.

Ownership flows. Foreign Institutional Investors (FII) have been trimming: down 1.50 percentage points quarter-on-quarter to 5.92% in Q1 FY27 (from 7.42% in Q4 FY26). Domestic Institutional Investors (DII) have added modestly, up 0.83pp to 6.01%. This suggests foreign money is de-risking amid leverage and execution questions, while domestic money remains cautious but holding. Promoter stake is stable at 54.87%.

Insider and block activity. No notable promoter or insider selling near the highs. The bulk/block deals noted (July 2026) were mutual fund (Elixir) trades at ₹166.61/₹166.30, not strategic moves. This is consistent with the street's view that the stock decline reflects fundamental concerns (margin pressure, debt load, execution delays) rather than distressed promoter or insider selling.

Valuation context. At ₹132.86, the stock sits in a no-man's-land: not so low that it screams value, not high enough to attract the growth premium it commanded at ₹362.9. The near-63% drawdown suggests the market has repriced execution risk (Flavour miss, Vanvate delay, margin compression) into a lower multiple. FII outflows confirm the street is waiting for proof of margin recovery and debt reduction before re-engaging. The honest read: the market is right to be cautious until H2 FY27 and March 2027 inventory normalization deliver.

The debate

What to watch next

The 2–3 concrete things that resolve the debate by Q3 FY27
  • 1 · Inventory normalization and working capital release

    Peak was September 2026. Management guided for normalization by March 2027. If October–Q3 FY27 sees inventory actually reducing and cash releasing, the working capital risk thesis weakens. If inventory holds or rises, interest burden will persist and the bear case gains weight.

  • 2 · Q3 FY27 margin recovery (OPM back above 13%)

    Q2 OPM fell to 12.4% from estimated 13.6% Q1. If Q3 margin bounces back toward 13%+, it signals Q2 was execution-driven softness, not structural deterioration. If margins stay 12–12.5%, it confirms near-term headwinds are stickier and the path to 15% is slower.

  • 3 · New geography (Germany, US, UK) revenue ramp and customer wins

    Q3–Q4 FY27 will tell if 12–18 month ramp assumption holds. Germany expected profitable by year-end; first customer revenue flow visible. If ramp is on pace and customer wins announced, execution confidence re-establishes. Delays here suggest aggressive guidance and lower near-term accretion.

What to track from here

Forget reported PAT for the next two quarters. Track EBITDA growth and EBITDA margin. EBITDA up 33% YoY is the real signal that operations are working. Once inventory normalizes (March 2027) and debt reduction begins, the leverage burden will ease and PAT will re-accelerate. But the through line for the next 6 months is whether EBITDA growth holds at 13–14% annually while the interest and depreciation drag gradually unwind.

S H Kelkar has delivered on revenue growth — 14.9% YoY is real and the long-term story remains structurally sound. But this quarter exposed a gap between the headline and the reality: margin compression, interest burden, Flavour guidance miss, and Vanvate delay. These are not fatal flaws, but they are not invisible either. The stock's 63% drawdown from its all-time high and FII outflows suggest the market is right to demand proof — not promise — of margin recovery and debt discipline. Hold for the structural story, but do not ignore the near-term headwinds. The number to track is EBITDA margin trajectory and working capital release starting March 2027. That will reset confidence.

Informational and educational content only. Not investment advice.